We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46 | -0.93% | 49.00 | 42.19 | 50.80 | 49.595 | 48.97 | 49.48 | 1,113,911 | 05:00:11 |
From May 2019 to May 2024
By Carlo Martuscelli
France's Sanofi SA said Monday that it will consolidate its six active pharmaceutical ingredient production sites into a new market-leading company which it will consider for a separate listing.
The new entity is expected to generate around 1 billion euros ($1.08 billion) in sales by 2022, and would be the second-largest API producer in the world, the drug maker said. A decision on an eventual spinoff on the Euronext Paris will be made by 2022. In the event of a public listing Sanofi said it will retain about a 30% stake in the company.
"This new entity would be agile as a standalone company, and able to unlock its growth potential, especially in capturing new third-party sales," said Philippe Luscan, executive vice president of global industrial affairs.
The company is expected to employee about 3,100 people, with headquarters in France. Sanofi said it intends to purchase ingredients from the new company in a long-term supply deal.
Write to Carlo Martuscelli at carlo.martuscelli@wsj.com; @carlomartu
(END) Dow Jones Newswires
February 24, 2020 10:38 ET (15:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
